Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
Healthcare
$0.31 -0.58%
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
52W Low $0.53High $2.35
Volume 2.77M
Average 3.79M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$93.33M
FY 2025 · Annual
Net Income
-$90.60M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| Gross Profit | (4.03M) | (8.71M) | (8.69M) | (8.47M) | (8.44M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 54.39M | 94.54M | 98.04M | 86.74M | 68.61M |
| Selling, General & Admin | 14.39M | 22.37M | 24.47M | 20.74M | 24.72M |
| Operating Expenses | 68.78M | 116.91M | 122.51M | 107.48M | 84.9M |
| Depreciation & Amortization | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| EBITDA | (68.7M) | (114.95M) | (115.4M) | (102.66M) | (82.16M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (72.81M) | (125.62M) | (131.19M) | (115.95M) | (93.33M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 108K | 1.95M | 7.06M | 4.74M | 2.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 85K | 1.96M | 7.11M | 4.82M | 2.73M |
| Income Before Tax | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| EPS (Diluted) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| 41.29M | 44.82M | 73.79M | 84.82M | 152.97M | |
| 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
TNYA Earnings Waterfall · TTM
NASDAQ:TNYA · Revenue to Net Income
Key Ratios
EPS$-0.47
Gross Margin-170.9%
Net Margin-2141.3%
P/E Ratio-1.8
P/S Ratio117.7
Analysis
$225.0K of revenue converted into -$83.0M of net income for the selected period. Gross margin is -170.9% and net margin is -2141.3%, showing how much revenue survives after costs and taxes. EPS is $-0.47, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| DEF 14A | DEF 14A filing | Oct 23, 2026 | |
| DEFA14A | DEFA14A filing | Oct 23, 2026 | |
| PRE 14A | PRE 14A filing | Oct 13, 2026 |
How much revenue does TNYA generate?
Tenaya Therapeutics, Inc. (TNYA) reported $0.00 of revenue in fiscal 2025.
Is TNYA profitable?
Tenaya Therapeutics, Inc. (TNYA) reported -$90.60M of net income.
Continue the stock analysis
Jump to another research area for this company.